TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32489675

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention for Loneliness (PAIL) - once-weekly group walk and health education workshop up to 90 min per session for 12 weeks.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-listed control group (WL) - no intervention during the study period.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention for Loneliness (PAIL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-listed control group (WL)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Focus group evaluations
Number of subjects: 48
Study: 35069013

Group type: EXPERIMENTAL
Intervention: Augmented Mindfulness-Based Cognitive Therapy (MBCT) combined with pharmacotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment dominated by pharmacotherapy (Control group)
Number of subjects: 160
Study: 33720857

Group type: EXPERIMENTAL
Intervention: Personalized balance games from the GAmification for Better LifE (GABLE) platform
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nintendo Wii games using a handheld Wii Remote
Number of subjects: 25
Study: 33284989

Group type: EXPERIMENTAL
Intervention: Contingent reinforcement plus usual smoking cessation care
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: More intensive behavioral smoking cessation support
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Multi-issue support
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Text-messaging support, e-cigarettes, cognitive behavioral therapy
Number of subjects: 1634
Study: 36435990

Group type: EXPERIMENTAL
Intervention: Early peanut introduction from infancy
Number of subjects: 0
Study: 32441198

Group type: EXPERIMENTAL
Intervention: Co-supplementation (50,000 IU vitamin D weekly + two omega-3 fatty acid capsules daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (two omega-3 fatty acid capsules daily + vitamin D placebo weekly)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU vitamin D weekly + omega-3 placebo daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (vitamin D placebo weekly + two omega-3 placebo capsules daily)
Number of subjects: 81
Study: 33844054

Group type: EXPERIMENTAL
Intervention: Double plating (3.5 LCP and 2.7 LCP plate in 90–90 configuration)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single plating (single 3.5 LCP plate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All specimens (including 4 without osteoporotic BMD)
Number of subjects: 12
Study: 33606914

Group type: COMPARATOR
Intervention: Y14 (extended-release peptide YY analogue), multiple doses between 9 and 36 mg, given at 7- to 14-day intervals over 28 days.
Number of subjects: 77
Study: 33165586

Group type: EXPERIMENTAL
Intervention: In-service nutrition education and counselling package
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 35042047

Group type: EXPERIMENTAL
Intervention: Intrapartum nipple stimulation therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 24
Study: 33161737

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis strain DE111
Number of subjects: 100
Study: 33249273

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg) + L-arginine (1.5 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 15
Study: 33244125

Group type: EXPERIMENTAL
Intervention: Pedagogical Questions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Direct Instruction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control content
Number of subjects: 72
Study: 32701682

Group type: EXPERIMENTAL
Intervention: Synthes 3.5‐mm LCP precontoured superior‐anterior clavicle plate (PCRP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Synthes 3.5‐mm LCP reconstruction plate (RP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Synthes 2.7‐mm cold‐worked calcaneal reconstruction plate with 6 bicortical screws (CRP6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Synthes 2.7‐mm cold‐worked calcaneal reconstruction plate with 8 bicortical screws (CRP8)
Number of subjects: 24
Study: 34559686

Group type: EXPERIMENTAL
Intervention: Olive oil applied to abdomens twice a day
Number of subjects: 156

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 156
Study: 33218535

Group type: EXPERIMENTAL
Intervention: Scapular Mobilization (SM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pectoralis Minor Stretching (PMS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combined Scapular Mobilization + Pectoralis Minor Stretching (SM + PMS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 52
Study: 36110080

Group type: EXPERIMENTAL
Intervention: Mtwo root canal preparation method modified by Mtwo machine nickel‐titanium file
Number of subjects: 96

Group type: COMPARATOR
Intervention: Modified Mtwo preparation method with synchronous root canal length measurement
Number of subjects: 96
Study: 33317156

Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Selenium yeast and coenzyme Q10
Number of subjects: 215
Study: 33161458

Group type: EXPERIMENTAL
Intervention: Project MIND training with a strong emphasis on role playing and skills rehearsal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Highly structured supervision and debriefing provided by a registered counsellor
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Providing mental health counselling in primary healthcare
Number of subjects: 18
Study: 35090544

Group type: EXPERIMENTAL
Intervention: Hyper‐mCBT program
Number of subjects: 248

Group type: COMPARATOR
Intervention: Barkley program (treatment-as-usual)
Number of subjects: 248
Study: 33031846

Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy (PBT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 144
Study: 32034072

Group type: EXPERIMENTAL
Intervention: Rindopepimut with bevacizumab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (keyhole limpet hemocyanin) with bevacizumab
Number of subjects: 73
Study: 33630453

Group type: EXPERIMENTAL
Intervention: Intraperitoneal Local Anesthetic (IPL)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravenous Local Anesthetic (IVL)
Number of subjects: 56
Study: 34474314

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (10 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 36148741

Group type: EXPERIMENTAL
Intervention: EPA supplementation (3 g/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DHA supplementation (3 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Olive oil control
Number of subjects: 28
Study: 32843251

Group type: EXPERIMENTAL
Intervention: Nonextraction therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Extraction of 4 first premolars
Number of subjects: 57
Study: 36305926

Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix (ADM) + Modified Coronally Advanced Tunnel Technique (MCAT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subepithelial Connective Tissue Graft (SCTG) + Modified Coronally Advanced Tunnel Technique (MCAT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patient satisfaction with esthetic outcome
Number of subjects: 24
Study: 34800099

Group type: EXPERIMENTAL
Intervention: Handheld fan used for 14 days
Number of subjects: 96
Study: 32917261

Group type: EXPERIMENTAL
Intervention: Random forest model for predicting acute myocardial infarction (AMI) < 1 month
Number of subjects: 85254

Group type: EXPERIMENTAL
Intervention: Random forest model for predicting all-cause mortality < 1 month
Number of subjects: 85254

Group type: EXPERIMENTAL
Intervention: AI prediction model validation with new patients for AMI < 1 month
Number of subjects: 85254

Group type: EXPERIMENTAL
Intervention: AI prediction model validation with new patients for all-cause mortality < 1 month
Number of subjects: 85254

Group type: COMPARATOR
Intervention: Comparative predictive accuracy of random forest model
Number of subjects: 85254
Study: 34435812

Group type: EXPERIMENTAL
Intervention: Asylum Seekers Photographic Interview (ASPI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-image-mediated narrative interview (Control)
Number of subjects: 36
Study: 33686879

Group type: EXPERIMENTAL
Intervention: Microcrystalline paclitaxel-coated balloon (mcPCB)
Number of subjects: 66
Study: 32448345

Group type: EXPERIMENTAL
Intervention: Intravenously administered remdesivir for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 0
Study: 36058795

Group type: EXPERIMENTAL
Intervention: CCHFV vaccine trial designed to capture infection as a trial endpoint
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CCHFV vaccine trial designed to capture clinical case as a trial endpoint
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CCHFV vaccine trial
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increased expected vaccine efficacy > 60%
Number of subjects: 150
Study: 34626502

Group type: EXPERIMENTAL
Intervention: Tanezumab (2.5 mg)
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Tanezumab (5 mg)
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study: 36106146

Group type: EXPERIMENTAL
Intervention: Glutamine (0.3 g kg FFM−1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 34537725

Group type: EXPERIMENTAL
Intervention: Standard Epidural Anaesthesia (SEA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Epidural Anaesthesia (HEA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral Paravertebral Anaesthesia (PVA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nuss procedure overall
Number of subjects: 60
Study: 32299513

Group type: EXPERIMENTAL
Intervention: HLX01 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (H-CHOP)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Reference rituximab plus CHOP (R-CHOP)
Number of subjects: 407
Study: 34132024

Group type: EXPERIMENTAL
Intervention: Topical C. rotundus oil
Number of subjects: 153

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 153

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 153
Study: 34319398

Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg, once daily
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 35739531

Group type: EXPERIMENTAL
Intervention: Scenario-based repetition strategy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Repetition (classical presentation)
Number of subjects: 162
Study: 32666599

Group type: EXPERIMENTAL
Intervention: Transplanted human fetal ganglionic eminence (treatment group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 54
Study: 36202546

Group type: EXPERIMENTAL
Intervention: Intracranial volume (ICV) measured by SAS
Number of subjects: 133

Group type: COMPARATOR
Intervention: Intracranial volume (ICV) measured by XYZ
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ICH volume (ICHV) measured by ABC/2
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ICHV/ICV and ICHV/CPV
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Midline shift and cistern effacement at baseline
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Old infarcts, leukoaraiosis, and brain atrophy
Number of subjects: 133
Study: 36240903

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Number of subjects: 655

Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 655
Study: 33210950

Group type: EXPERIMENTAL
Intervention: Decision trees
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Online planning tool
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Infographics
Number of subjects: 500
Study: 34741886

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: HER4 mutations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E395K, G815R, or R929W HER2 mutations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Other second/third-generation (2G/3G) TKIs
Number of subjects: 23
Study: 32472172

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab alone (n=23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Combination of intravitreal ranibizumab and panretinal photocoagulation (PRP) (n=24)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (ranibizumab alone and combination)
Number of subjects: 47
Study: 33992882

Group type: EXPERIMENTAL
Intervention: Low monoenergetic images
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional images
Number of subjects: 42
Study: 35641440

Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation system (FIS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Air-fluidised bed (AFB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation system (FIS) with ClimateCare®
Number of subjects: 80
Study: 33715064

Group type: EXPERIMENTAL
Intervention: Conventional Anesthesia (CA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vibrational Anesthesia (VBA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Computer-Controlled Local Anesthesia Device (CCLAD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Disruptive Behavior (FLACC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Anxiety (VPTm)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Physiological Parameters (SBP, DBP, HR, SpO2, RR)
Number of subjects: 35
Study: 32236507

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg/d) for 2 years
Number of subjects: 908

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 908
Study: 35810751

Group type: EXPERIMENTAL
Intervention: Niraparib plus nivolumab
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Niraparib plus ipilimumab
Number of subjects: 91
Study: 33551297

Group type: EXPERIMENTAL
Intervention: Male transobturator sling
Number of subjects: 380

Group type: COMPARATOR
Intervention: Artificial urinary sphincter (AUS)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 380
Study: 34641791

Group type: EXPERIMENTAL
Intervention: Doll Therapy (DT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 52
Study: 32812051

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 62
Study: 35460287

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg (TIL100)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg (TIL200)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (both dosages)
Number of subjects: 26
Study: 34769704

Group type: EXPERIMENTAL
Intervention: VR with light pressure (VRL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VR with moderate pressure (VRM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: General warm up (GW)
Number of subjects: 15
Study: 36172885

Group type: EXPERIMENTAL
Intervention: 70 g mycoprotein (MYC; 31.4 g protein, 2.5 g leucine; n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 38.2 g of a protein concentrate obtained from mycoprotein (PCM; 28.0 g protein, 2.5 g leucine; n=12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both MYC and PCM
Number of subjects: 24
Study: 33768643

Group type: EXPERIMENTAL
Intervention: Minimal supplementation
Number of subjects: 635
Study: 35180745

Group type: EXPERIMENTAL
Intervention: Lateral cutaneous branch (LCB) of the fourth intercostal nerve
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anterior cutaneous branch (ACB) of the third intercostal nerve
Number of subjects: 19
Study: 34008421

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Aspirin or Clopidogrel (Control)
Number of subjects: 45
Study: 36274187

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Improved biomass arm
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Liquified petroleum gas (LPG) arm
Number of subjects: 1414
Study: 33151500

Group type: EXPERIMENTAL
Intervention: Bumetanide oral liquid formulation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 32387408

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 80 μg delivered via Breezhaler®
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 320 μg delivered via Breezhaler®
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 80 μg and 320 μg delivered via Breezhaler®
Number of subjects: 739

Group type: COMPARATOR
Intervention: Mometasone furoate 200 μg and 800 μg delivered via Twisthaler®
Number of subjects: 739
Study: 35192784

Group type: EXPERIMENTAL
Intervention: Tested PCV13
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control PCV13
Number of subjects: 1200
Study: 33596092

Group type: EXPERIMENTAL
Intervention: Immobilization in 60° of external rotation plus 30° of abduction (group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Arthroscopic Bankart repair (group 2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 112
Study: 32124817

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with 45° head rotation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with no head rotation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Volunteers
Number of subjects: 80
Study: 33687555

Group type: EXPERIMENTAL
Intervention: MINST + NaOCl gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: MINST alone
Number of subjects: 40
Study: 32394686

Group type: EXPERIMENTAL
Intervention: del Nido solution (DNS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: cold blood cardioplegia solution (CBCS)
Number of subjects: 60
Study: 35984512

Group type: EXPERIMENTAL
Intervention: 200 ppm F/TMP/XE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16% xylitol + 4% erythritol (XE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 200 ppm F + 0.2% TMP (200 ppm F/TMP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1100 ppm F
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (no F, TMP, XE)
Number of subjects: 120
Study: 33617294

Group type: EXPERIMENTAL
Intervention: DECTA with 50% reduced iodine dose (300 mgI/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DECTA-80%
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DECTA-40%
Number of subjects: 65

Group type: COMPARATOR
Intervention: SECTA with standard iodine dose (600 mgI/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DECTA
Number of subjects: 65

Group type: COMPARATOR
Intervention: SECTA
Number of subjects: 65
Study: 33965769

Group type: EXPERIMENTAL
Intervention: Nitrate exposure >25 mg/L (preconception)
Number of subjects: 1219140

Group type: EXPERIMENTAL
Intervention: Nitrate exposure >25 mg/L (prenatal)
Number of subjects: 1219140

Group type: EXPERIMENTAL
Intervention: Nitrate exposure >25 mg/L (postnatal)
Number of subjects: 1219140

Group type: EXPERIMENTAL
Intervention: Nitrate exposure (continuous)
Number of subjects: 1219140
Study: 35881863

Group type: EXPERIMENTAL
Intervention: Cacao butter
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mother's milk
Number of subjects: 72
Study: 32642971

Group type: EXPERIMENTAL
Intervention: PGX (15–20 g/day)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo (isocaloric rice flour, 6.4–8.6 g/day)
Number of subjects: 290
Study: 32830200

Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment (n = 71)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-gemcitabine treatment (n = 59)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Validation cohort gemcitabine subgroup (n = 94)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Validation cohort non-gemcitabine subgroup (n = 19)
Number of subjects: 130
Study: 33948084

Group type: EXPERIMENTAL
Intervention: Mesoporous delivery system
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 33233275

Group type: EXPERIMENTAL
Intervention: Cultivar BRS Moema
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cultivar Airetama
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Overall chemical composition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: pH
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: CAR and PHE
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: MASS and PLAS
Number of subjects: 2
Study: 37779541

Group type: EXPERIMENTAL
Intervention: GSK3772847 (10 mg/kg intravenous)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 34060142

Group type: EXPERIMENTAL
Intervention: Regimen A (diaper with emollient and apertures on the inner liner, acidic pH-buffered wipe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen B (non-emollient, non-aperture containing topsheet and wipe with limited buffering capacity)
Number of subjects: 0
Study: 32044419

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin (PacCis)‐CRT; paclitaxel 20 mg/m2 on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 mg/m2, days 1‐4 and 29‐32; RT to a total dose of 63.6 Gy
Number of subjects: 221

Group type: COMPARATOR
Intervention: Fluorouracil/cisplatin (CisFU)‐CRT; fluorouracil 600 mg/m2; cisplatin 20 mg/m2, days 1‐5 and 29‐33; RT: 70.6 Gy
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin (PacCis)‐CRT
Number of subjects: 221

Group type: COMPARATOR
Intervention: Fluorouracil/cisplatin (CisFU)‐CRT
Number of subjects: 221
Study: 35388330

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Hemodiafiltration
Number of subjects: 92
Study: 33886898

Group type: EXPERIMENTAL
Intervention: Educational technology intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison group (no educational technology)
Number of subjects: 73